Fosamax Manufacturer Urges High Court Review Of ‘Outlier’ Preemption Ruling
WASHINGTON, D.C. — High court review is needed again in the long-running Fosamax femur fracture multidistrict litigation, the drug manufacturer says in a petition for certiorari, arguing that the Third Circuit...To view the full article, register now.
Already a subscriber? Click here to view full article